Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?

To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A [n = 40], B [n = 60], and C [n = 143]) according to the proximity of their gastrointesti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Kim, Tae Hyun, Park, Joong-Won, Kim, Bo Hyun, Kim, Hyunjung, Moon, Sung Ho, Kim, Sang Soo, Woo, Sang Myung, Koh, Young-Hwan, Lee, Woo Jin, Kim, Dae Yong, Kim, Chang-Min
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6406298/
https://ncbi.nlm.nih.gov/pubmed/30781391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020230
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak